RCKT insider trading
NasdaqGM HealthcareROCKET PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Company website: www.rocketpharma.com
RCKT insider activity at a glance
FilingIQ has scored 258 insider transactions for RCKT since Apr 2, 2018. The most recent filing in our index is dated May 13, 2026.
Across the full history, 11 open-market purchases
and 116 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RCKT insider trades is 56.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RCKT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding RCKT
Frequently asked
- How many insider trades does FilingIQ track for RCKT?
- FilingIQ tracks 258 Form 4 insider transactions for RCKT (ROCKET PHARMACEUTICALS, INC.), covering filings from Apr 2, 2018 onwards. 7 of those were filed in the last 90 days.
- Are RCKT insiders net buyers or net sellers?
- Across the full Form 4 history for RCKT, 11 transactions (4%) were open-market purchases and 116 (45%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RCKT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RCKT in?
- ROCKET PHARMACEUTICALS, INC. (RCKT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $481.59M.
Methodology & sources
Every RCKT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.